| __timestamp | AstraZeneca PLC | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 1595000 |
| Thursday, January 1, 2015 | 5997000000 | 11434000 |
| Friday, January 1, 2016 | 5890000000 | 26546000 |
| Sunday, January 1, 2017 | 5757000000 | 39778000 |
| Monday, January 1, 2018 | 5932000000 | 53418000 |
| Tuesday, January 1, 2019 | 5958000000 | 111997000 |
| Wednesday, January 1, 2020 | 5991000000 | 139507000 |
| Friday, January 1, 2021 | 9736000000 | 195958000 |
| Saturday, January 1, 2022 | 9762000000 | 248149000 |
| Sunday, January 1, 2023 | 10935000000 | 232366000 |
| Monday, January 1, 2024 | 13583000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC has consistently outpaced ImmunityBio, Inc. in R&D investment. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking at approximately $10.9 billion in 2023. This strategic focus underscores AstraZeneca's dedication to advancing its drug pipeline and maintaining its market leadership.
Conversely, ImmunityBio, Inc., while showing growth, has maintained a more modest R&D budget, increasing from $1.6 million in 2014 to around $232 million in 2023. This represents a staggering growth of over 14,000%, highlighting its aggressive push into the biotech arena. The contrasting R&D strategies of these two companies reflect their differing scales and market strategies, offering a fascinating glimpse into the dynamics of pharmaceutical innovation.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and HUTCHMED (China) Limited
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and ImmunityBio, Inc.
Research and Development Investment: Alpine Immune Sciences, Inc. vs ImmunityBio, Inc.
R&D Spending Showdown: CymaBay Therapeutics, Inc. vs ImmunityBio, Inc.
Comparing Innovation Spending: Xenon Pharmaceuticals Inc. and ImmunityBio, Inc.
Analyzing R&D Budgets: ImmunityBio, Inc. vs Travere Therapeutics, Inc.